Celmatix Announces Achievement of Key Preclinical Milestones in Premature Menopause Prevention Drug Program
NEW YORK, May 17 (Bernama-BUSINESS WIRE) — Celmatix Inc. a biotechnology company focused on ovarian biology, today announced the identification of a novel AMHR2 agonist compound that has demonstrated robust biological activity in multiple therapeutically relevant preclinical assays and a pharmacokinetic profile consistent with the desired product profile for an…

